Univest
Univest
  • Markets

Astrazeneca Pharma India Ltd. (ASTRAZEN): AstraZeneca Pharma Share Price Rises 5.11% to Rs 6,383.70 Today

  • October 28, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
AstraZeneca Pharma Share Price
Astrazeneca Pharma India Ltd. (ASTRAZEN) share price rose to Rs 6,383.7 today, up 5.11% from the previous close. Market cap was Rs 15,182.75 crore.

AstraZeneca Pharma share price stands at Rs 6,383.70 as of 28 October 2026 at 11:37 AM IST, up Rs 310.60 or 5.11% from the previous close of Rs 6,073.10. The pharmaceutical company carries a market capitalisation of Rs 15,182.75 crore, and the AstraZeneca Pharma share price rise is the event this update examines.

Univest figures confirm the price action, but they do not point to a specific company trigger. The AstraZeneca Pharma stock is gaining today on price action alone, so this report stays with what the latest Univest figures show: the day’s range, valuation multiples, capital returns, the industry benchmark and listed peers.

Table of Contents

Toggle
  • AstraZeneca Pharma Share Price Today: Price Action Analysis
  • Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching AstraZeneca Pharma
  • About AstraZeneca Pharma
  • Frequently Asked Questions
    • Why is AstraZeneca Pharma share price rising today?
    • What is the AstraZeneca Pharma share price today?
    • What is the market capitalisation of AstraZeneca Pharma?
    • What is the P/E ratio of AstraZeneca Pharma?
    • What is the ROCE of AstraZeneca Pharma?
    • What are the EPS and book value of AstraZeneca Pharma?
    • Does AstraZeneca Pharma pay a dividend?
    • How does AstraZeneca Pharma compare with pharmaceutical peers?
  • Track AstraZeneca Pharma Share Price on Univest

AstraZeneca Pharma Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 6,383.7
Previous Close Rs 6,073.1
Today's Move Rs 310.6 (+5.11%)
Open Rs 6,058.5
High Rs 6,383.7
Low Rs 6,058.5
Market Capitalisation Rs 15,182.75 crore
Market Cap Category Mid Cap

For readers following the AstraZeneca Pharma share price today, the points to monitor next are how the stock holds against its day high of Rs 6,383.70, how its P/E ratio of 89.51 compares with the industry median of 30.74, and how its ROCE of 31.24% stacks up against pharmaceutical peers.

Astrazeneca Pharma India Ltd. (ASTRAZEN) rose to Rs 6,383.7 from the previous close of Rs 6,073.1, a move of Rs 310.6 or 5.11%. The stock opened at Rs 6,058.5, reached a high of Rs 6,383.7, recorded a low of Rs 6,058.5.

AstraZeneca Pharma share price traded at Rs 6,383.70, a gain of Rs 310.60 or 5.11% over the previous close of Rs 6,073.10. The stock opened at Rs 6,058.50, below that previous close, and has moved between Rs 6,058.50 and Rs 6,383.70 so far today.

The day low of Rs 6,058.50 is below the previous close of Rs 6,073.10, so the stock dipped under its prior reference level at one point today. That low equals the opening price, so the stock has not traded below its open so far today. The last traded price of Rs 6,383.70 is the day high, and it is Rs 325.20 above the opening level. The AstraZeneca Pharma share price update therefore shows a gain of 5.11% on the previous close.

With the price move laid out, the next question is what the company’s reported fundamentals add to the picture of AstraZeneca Pharma stock performance.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric Value
Market Capitalisation Rs 15,182.75 crore
P/E Ratio 89.51x
P/B Ratio 16.79x
ROE 23.02%
ROCE 31.24%
EPS Rs 67.85
Book Value Per Share Rs 361.68
Dividend Yield 0.59%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 89.51x, P/B 16.79x, ROE 23.02%, ROCE 31.24%. Taken on their own, these numbers offer context rather than a trading signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15,182.75 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 89.51x, P/B at 16.79x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.59%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.74x, median ROE of 11.23%, median ROCE of 13.17%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 89.51x
Benchmark Median P/E 30.74x
Benchmark Average P/E 43.3x
Benchmark P/E Range 3.21x to 577.05x
Company P/B Ratio 16.79x
Benchmark Median P/B 2.71x
Company ROE 23.02%
Benchmark Median ROE 11.23%
Company ROCE 31.24%
Benchmark Median ROCE 13.17%
Company Market Capitalisation Rs 15,182.75 crore
Benchmark Median Market Cap Rs 696.43 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 89.51x, which is above the benchmark median of 30.74x, a difference of +191.18%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.23%, a difference of +104.99%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.17%, a difference of +137.21%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries Ltd. SUNPHARMA 4,18,204.09 34.91 4.88 14.85 19.11
Divi's Laboratories Ltd. DIVISLAB 2,40,780 86.02 14.25 16.19 21.51
Torrent Pharmaceuticals Ltd. TORNTPHARM 1,73,828.11 82.48 9.53 26.76 19.27
Zydus Lifesciences Ltd. ZYDUSLIFE 1,15,520.92 25.79 4.32 19.69 21.39
Laurus Labs Ltd. LAURUSLABS 1,11,304.32 105.74 20.5 18.31 18.2

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 89.51x compared with the displayed peer median of 82.48x. The comparison is relative and should not be read as a recommendation. Its ROE of 23.02% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,182.75 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching AstraZeneca Pharma

Investors tracking AstraZeneca Pharma can follow the price move, the valuation and capital-return figures and the sector benchmark. Each point below rests on figures from the latest Univest data and none implies a recommendation or a forecast.

  • Price action: the stock is up 5.11% at Rs 6,383.70, with a day range of Rs 6,058.50 to Rs 6,383.70.
  • Capital returns: ROCE of 31.24% is above the Healthcare benchmark median of 13.17%.
  • Valuation: P/E of 89.51 is above the industry median of 30.74, and P/B of 16.79 is above the median of 2.71.
  • Per-share figures: EPS of Rs 67.85 and book value of Rs 361.68 per share frame the valuation multiples.
  • Size: market capitalisation of Rs 15,182.75 crore compares with an industry median of Rs 696.43 crore.

About AstraZeneca Pharma

Astrazeneca Pharma India Ltd. is a listed company operating in the Healthcare sector and the Pharmaceuticals & Drugs industry, according to latest Univest data. Within its same-industry benchmark group of 199 companies, it has a market capitalisation of Rs 15,182.75 crore, EPS of Rs 67.85 and a book value of Rs 361.68 per share.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why is AstraZeneca Pharma share price rising today?

Ans. Univest figures confirm the price action, but they do not point to a specific company trigger. The stock traded at Rs 6,383.70, up 5.11% from the previous close of Rs 6,073.10, as of 28 October 2026 at 11:37 AM IST.

What is the AstraZeneca Pharma share price today?

Ans. The AstraZeneca Pharma share price was Rs 6,383.70 at 11:37 AM IST on 28 October 2026. That is a rise of Rs 310.60, or 5.11%, from the previous close of Rs 6,073.10, after an opening price of Rs 6,058.50.

What is the market capitalisation of AstraZeneca Pharma?

Ans. AstraZeneca Pharma has a market capitalisation of Rs 15,182.75 crore. That is above the Pharmaceuticals & Drugs industry benchmark median of Rs 696.43 crore and above the benchmark average of Rs 13,492.66 crore across 199 companies.

What is the P/E ratio of AstraZeneca Pharma?

Ans. The AstraZeneca Pharma P/E ratio is 89.51. The Pharmaceuticals & Drugs industry benchmark has a median P/E of 30.74 and an average of 43.30, so the company sits above the median and above the average.

What is the ROCE of AstraZeneca Pharma?

Ans. AstraZeneca Pharma has a ROCE of 31.24%, which measures returns generated on capital employed. The industry benchmark median ROCE is 13.17% and the average is 12.81%, so the company figure is above the median and above the average.

What are the EPS and book value of AstraZeneca Pharma?

Ans. AstraZeneca Pharma has an EPS of Rs 67.85, showing earnings attributable to each share, and a book value of Rs 361.68 per share. The P/B ratio is 16.79, against an industry median of 2.71.

Does AstraZeneca Pharma pay a dividend?

Ans. The latest Univest data shows a dividend yield of 0.59% for AstraZeneca Pharma. Dividend yield describes the historical or current payout relative to the share price and is not a guarantee of any future payout.

How does AstraZeneca Pharma compare with pharmaceutical peers?

Ans. The AstraZeneca Pharma P/E of 89.51 is lower than 1 of 5 listed peers and higher than 4. Its ROCE of 31.24% is higher than 5 of 5 listed peers, and its market capitalisation is smaller than each peer.

Track AstraZeneca Pharma Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Users can track the live AstraZeneca Pharma share price on Univest, along with fundamental ratios such as P/E, P/B and ROCE, 52-week levels and wider market insights. The AstraZeneca Pharma share price today of Rs 6,383.70 and the 5.11% rise are part of a market update, not a recommendation, and the figures here will move as the day’s trade continues.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply